{"classes":[{"categories":[{"measurements":[{"comment":"NA means Not Estimable due to data not mature (lack of events observed being lower than 50%)","groupId":"OG000","lowerLimit":"7.2","upperLimit":"NA","value":"NA"},{"comment":"NA means Not Estimable due to data not mature (lack of events observed being lower than 50%)","groupId":"OG001","lowerLimit":"6.7","upperLimit":"NA","value":"NA"}]}],"title":"Median duration of response (IRC)"},{"categories":[{"measurements":[{"comment":"NA means Not Estimable due to data not mature (lack of events observed being lower than 50%)","groupId":"OG000","lowerLimit":"7.0","upperLimit":"NA","value":"8.3"},{"groupId":"OG001","lowerLimit":"5.3","upperLimit":"18.0","value":"8.8"}]}],"title":"Median duration of response (investigator)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"11.2","value":"8.4"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"11.0","value":"6.9"}]}],"title":"Median progression free survival (IRC)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"10.9","value":"8.3"},{"groupId":"OG001","lowerLimit":"5.5","upperLimit":"8.3","value":"6.8"}]}],"title":"Median progression free survival (investigator)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized to receive sunvozertinib 200 mg once daily continuously.","id":"OG000","title":"Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized to receive sunvozertinib 300 mg once daily continuously.","id":"OG001","title":"Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Through the study completion, an average of around 1 year for part B","title":"Part B: DoR, PFS According to RECIST 1.1 Using Assessments Performed by an IRC; DoR, PFS Using Investigators Assessments According to RECIST 1.1","type":"SECONDARY","unitOfMeasure":"months"}